human
parainfluenza
viru
hpiv
infect
aetiolog
acut
viral
myocard
rare
case
report
literatur
date
report
case
fulmin
myocard
yearold
man
viraemia
success
treat
intraven
ribavirin
intraven
immunoglobulin
ivig
current
recommend
treatment
hpiv
myocard
knowledg
first
report
patient
document
viraemia
subsequ
clear
initi
antivir
therapi
although
difficult
definit
attribut
patient
clinic
improv
ribavirin
ivig
alon
case
suggest
clinician
may
wish
consid
initi
ribavirin
ivig
patient
hpiv
myocard
persist
viraemia
respond
support
measur
alon
elsevi
bv
right
reserv
acut
myocard
complex
challeng
diagnosi
pathogenesi
diseas
frequent
involv
viral
infect
amongst
viral
caus
acut
myocard
human
parainfluenza
viru
hpiv
infect
aetiolog
rare
four
case
report
literatur
two
case
myocard
associ
hpiv
infect
diagnos
rise
pair
serolog
posit
viral
cultur
throat
swab
recent
report
hpiv
myocard
demonstr
presenc
ribonucl
acid
rna
nasopharyng
swab
pericardi
fluid
cardiac
tissu
case
howev
diagnos
retrospect
aetiolog
inform
influenc
case
manag
best
knowledg
first
report
case
myocard
document
viraemia
clearanc
viraemia
follow
treatment
intraven
iv
ribavirin
immunoglobulin
ivig
correspond
author
tel
fax
email
address
lowchianyong
sghcomsg
chianyong
low
yahoocomsg
cy
low
previous
well
man
present
region
hospit
histori
dyspnoea
chest
pain
lower
limb
swell
dri
cough
without
fever
week
prior
admiss
admiss
afebril
normotens
tachycard
oxygen
satur
breath
room
air
physic
examin
reveal
sign
consist
cardiac
failur
full
blood
count
reveal
mild
leukocytosi
white
cell
count
l
neutrophil
lymphocyt
monocyt
thrombocytosi
l
creactiv
protein
margin
elev
mgl
procalcitonin
level
normal
acut
renal
failur
elev
creatinin
mmoll
cardiac
enzym
creatin
kinas
ck
creatin
kinasemb
fraction
ckmb
troponin
elev
ul
ul
gl
respect
transthorac
echographi
show
reduc
left
ventricular
eject
fraction
lvef
global
hypokinesia
presumpt
diagnosi
viral
myocard
made
deterior
rapidli
requir
mechan
ventil
respiratori
failur
along
doubl
inotrop
intraarteri
balloon
pump
iabp
support
cardiogen
shock
develop
worsen
renal
failur
well
paroxysm
episod
atrial
fibril
endotrach
tube
aspir
neg
influenza
viru
b
adenoviru
respiratori
syncyti
viru
rsv
immunofluoresc
one
week
admiss
deterior
start
extracorpor
membran
oxygen
ecmo
transfer
hospit
transfer
still
ongo
myocardi
inflamm
persist
rais
cardiac
enzym
test
elucid
possibl
infect
aetiolog
myocard
includ
neg
polymeras
chain
reaction
pcr
serum
parvoviru
epsteinbarr
viru
herp
simplex
viru
human
viru
human
immunodefici
viru
screen
cytomegaloviru
igm
brucella
rickettsi
serolog
neg
stool
enteroviru
pcr
test
nasopharyng
swab
sent
respiratori
viru
multiplex
pcr
neg
rsv
influenza
b
metapneumoviru
rhinoviru
coronaviru
adenoviru
howev
posit
seeplex
respiratori
viral
detect
assay
seegen
rockvil
luminex
xtag
respiratori
viral
panel
luminex
corpor
primer
specif
design
research
laboratori
program
emerg
infecti
diseas
peid
dukenu
graduat
medic
school
use
complet
genom
viral
serotyp
download
genbank
align
mafft
multipl
sequenc
program
align
amino
acid
nucleotid
sequenc
geneiou
pro
version
forward
revers
primer
sequenc
design
target
highli
conserv
region
produc
amplicon
kb
length
primer
use
hpiv
hpiv
f
hpiv
pcr
reaction
carri
use
pfu
ultra
tm
polymeras
util
primer
set
patient
serum
also
test
posit
pcr
indic
ongo
viraemia
fig
sequenc
bp
product
sit
within
v
gene
show
similar
sequenc
deposit
genbank
access
number
confirm
aetiolog
myocard
patient
follow
detect
patient
start
oral
ribavirin
load
dose
mgkg
day
mg
three
time
daili
day
switch
iv
ribavirin
mgkg
hourli
day
total
durat
day
upon
receiv
regulatori
approv
health
scienc
author
singapor
intraven
immunoglobulin
ivig
given
concomitantli
dose
gkg
everi
day
week
patient
remain
cardiogen
shock
left
ventricular
assist
devic
lvad
implant
day
iv
ribavirin
start
day
initi
hospit
present
histolog
examin
left
ventricular
apic
tissu
reveal
featur
keep
lymphocyt
viral
myocard
fig
well
microscop
foci
consist
myocardi
ischaemia
also
coagul
necrosi
granul
foci
show
vari
degre
organ
keep
acut
chronic
ongo
myocardi
ischaemia
follow
iv
ribavirin
initi
viraemia
clearanc
monitor
use
peid
rtpcr
assay
design
detect
bp
genom
show
serial
declin
hpiv
viraemia
clearanc
day
ribavirin
therapi
fig
along
improv
myocardi
inflamm
reflect
normal
cardiac
enzym
fig
patient
toler
ribavirin
evid
haemolyt
anaemia
worsen
renal
function
transthorac
echocardiogram
perform
week
ribavirin
treatment
show
improv
lvef
postop
recoveri
complic
bleed
caus
mediastin
haematoma
thrombosi
caus
transient
dysphas
stroke
also
suffer
mediastin
requir
prolong
cours
antibiot
antifung
therapi
undergo
month
rehabilit
recov
lvef
subsequ
underw
success
explant
lvad
one
year
first
present
myocard
report
demonstr
hpiv
aetiolog
viral
myocard
previous
report
case
tabl
diagnosi
made
pair
serolog
serolog
hpiv
howev
lack
specif
due
cross
reactiv
direct
envelop
glycoprotein
hn
f
protein
paramyxovirus
henc
may
difficult
interpret
other
diagnosi
establish
posit
immunofluoresc
cultur
viru
throat
swab
one
case
report
isol
viral
rna
throat
swab
well
endomyocardi
tissu
use
molecular
techniqu
current
report
identifi
pcr
nasopharyng
swab
serum
patient
acut
myocard
histopatholog
examin
cardiac
tissu
also
show
featur
consist
viral
myocard
knowledg
first
report
success
clearanc
viraemia
ribavirin
antivir
therapi
myocard
wellrecogn
sequela
sever
viral
infect
coxsacki
viru
parvoviru
type
b
adenoviru
frequent
viral
etiolog
implic
hpiv
myocard
rare
seldom
report
entiti
remain
unclear
differ
virul
present
prognosi
four
serotyp
patient
appear
recov
spontan
minim
support
treatment
other
requir
support
ecmo
follow
heart
transplant
patient
develop
cardiac
failur
requir
inotrop
ecmo
support
week
develop
influenzalik
ill
although
ventricular
assist
devic
becom
wide
use
patient
cardiac
failur
vari
etiolog
much
success
implant
devic
patient
viral
myocard
pose
technic
challeng
cardiac
tissu
patient
often
inflam
friabl
increas
risk
bleed
subsequ
infect
antivir
agent
evalu
treatment
acut
myocard
anim
model
small
case
seri
ribavirin
synthet
nucleosid
togeth
interferon
alpha
improv
surviv
mice
administ
time
viru
inocul
ivig
antivir
immun
modulatori
effect
use
vari
success
patient
acut
myocard
howev
case
report
use
ribavirin
ivig
treatment
hpiv
myocard
human
although
hpiv
viraemia
test
time
present
presenc
persist
myocardi
inflamm
identif
hpiv
viraemia
week
admiss
suggest
ongo
protract
hpiv
viraemia
definit
guidelin
use
ribavirin
ivig
hpiv
myocard
follow
regim
use
khanna
et
al
case
seri
haematolog
patient
rsv
respiratori
tract
infect
demonstr
safeti
efficaci
dose
iv
ribavirin
mgkg
hourli
ivig
gkg
everi
day
use
case
day
inde
initi
ribavirin
ivig
patient
result
prompt
resolut
viraemia
also
improv
patient
left
ventricular
eject
fraction
follow
clearanc
viraemia
conced
howev
difficult
definit
attribut
improv
ribavirin
ivig
therapi
concomit
placement
lvad
although
test
patient
would
interest
check
serolog
statu
patient
term
presenc
humor
respons
ivig
treatment
ensur
patient
suffer
specif
gener
form
immunodefici
summari
report
case
myocard
viraemia
respond
antivir
immun
modulatori
therapi
current
recommend
treatment
acut
hpiv
myocard
clinician
may
wish
consid
iv
ribavirin
ivig
therapi
especi
set
persist
viraemia
respond
support
measur
alon
none
none
declar
requir
